Tin tức & Cập nhật
Xem bài viết Ung thư
Xem

Rucaparib extends time to subsequent therapy in advanced ovarian cancer
In patients with newly diagnosed advanced ovarian cancer, treatment with rucaparib delays the median time to first and second subsequent anticancer therapy for almost 1 year relative to placebo, according to a study presented at ESMO Gyn 2026.

Dostarlimab plus chemo prolongs survival in advanced dMMR/MSI-H endometrial cancer
Treatment with dostarlimab combined with carboplatin and paclitaxel (CP) confers sustained long-term progression-free survival (PFS) and overall survival (OS) benefits on patients with primary advanced or recurrent deficient mismatch repair and microsatellite instability-high (dMMR/MSI-H) endometrial cancer, as shown by the results of the phase III RUBY trial.

Denosumab superior to alendronate for BMD loss prevention in malignant lymphoma
The use of denosumab demonstrates superior protection against bone mineral density (BMD) loss at 12 months compared with alendronate in older patients with newly diagnosed lymphoma receiving R-CHOP* and related regimens, as shown in the DENOSULY study.

ARACOG: Is there a difference in cognitive effects between darolutamide and enzalutamide?
ARACOG, a phase II randomized trial, reports a significantly greater decline in objectively assessed cognitive function for advanced prostate cancer patients treated with enzalutamide vs darolutamide over 24 weeks, according to data presented at ASCO 2026.




